GET DAILY SIGNALSWhy Is Rigel Pharmaceuticals (RIGL) Stock Down -11.09% Today?
Key Takeaways
- Shares fell about 11.09% to roughly $40.64, extending a sharp post-earnings selloff from the prior session's close of $45.71.
- Primary catalyst: third-quarter earnings came in below consensus, with full-year revenue guidance narrowed below analyst expectations.
- Secondary driver: a decline in the company's cash position and broad weakness across small- and mid-cap biotechnology names.
- Broader context: healthcare and biotech stocks were under pressure amid rising rate expectations and a risk-off tone in the sector.
- What traders are watching next: upcoming R289 data at the American Society of Hematology (ASH) meeting in December and any further guidance updates.
- Explore additional details on Price Targets, Earnings, and Forecast pages for deeper analysis of this ticker.
- Discover how AI-driven strategies are navigating current market conditions on the Trending AI Robots page.
Opening Summary
Rigel Pharmaceuticals, Inc. (RIGL), a South San Francisco-based commercial-stage biotechnology company focused on hematologic disorders and cancer, extended its slide in Friday trading, with shares down roughly 11.09% to about $40.64 from a prior close of $45.71. The decline marks the second consecutive session of double-digit percentage losses for the developer of TAVALISSE and REZLIDHIA, as investors continued to digest a third-quarter earnings report that fell short of Wall Street's profit expectations while delivering mixed guidance for the year ahead.
Earnings Miss Overshadows Revenue Beat
The sharpest driver of the move was Rigel's latest quarterly report. The company posted earnings per share of $0.70, missing the $0.95 consensus estimate, even as revenue of $80.9 million narrowly topped the roughly $80 million analysts had projected. Record net product sales of $72.3 million, up about 13% year over year, highlighted solid commercial execution, but the bottom-line shortfall — driven by higher costs and a less favorable expense mix — weighed heavily on sentiment.
Guidance Narrows Below Consensus
Investor reaction was further pressured by the company's updated outlook. Management narrowed its full-year revenue guidance to a range of $290 million to $295 million. While the move effectively raised the low end of the prior range, the midpoint still sits below the roughly $305.7 million analysts had been modeling. For a growth-oriented biotech trading at a premium earlier this year, the softer-than-expected top-line trajectory gave traders a concrete reason to reduce exposure.
Cash Position and Sector Pressure Add to Selling
Alongside the earnings details, a decline in the company's cash balance to about $99.3 million drew scrutiny from investors assessing runway and flexibility. The move also coincided with broader weakness in healthcare and biotechnology equities, where a risk-off tone and rising rate expectations pressured speculative and small-cap names. Rigel's beta above 1.0 amplifies this sensitivity, leaving the stock vulnerable to sector-wide de-risking even as its own fundamentals remain the primary focus.
Market Context and Trading Activity
Trading volume was elevated relative to the stock's roughly 256,000-share three-month average, reflecting the concentration of activity around the earnings catalyst. The decline has pushed RIGL decisively below the levels it held through late October and early November, and well off its 52-week high near $52. The stock's slide diverged from a mixed tape in the broader market, underscoring that company-specific factors — rather than a broad index move — drove the action. Technically, the break below the prior session's low signals continued downside momentum in the near term.
What Comes Next for RIGL
Looking ahead, the key catalyst on the horizon is the presentation of R289 data at the ASH annual meeting in December, which could refocus attention on the company's pipeline rather than near-term earnings. Traders will also monitor management commentary on cash management, product sales momentum, and any refinements to the full-year outlook. Risks include further sector-wide pressure on biotech valuations, execution risk on commercialization, and the potential for additional downward revisions to consensus estimates. On the other hand, a favorable readout or improved guidance could support a stabilization in the share price following this week's sharp repricing.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots designed to identify opportunities across thousands of tickers. Tickeron offers hundreds of these bots, each varying by strategy, timeframe, performance metrics, and the symbols they trade, but only the strongest performers under current market conditions are featured in this section. Explore the Trending AI Robots page to see which automated strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
RIGL sees MACD Histogram crosses below signal line
RIGL saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 05, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 38 instances where the indicator turned negative. In 36 of the 38 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 59 cases where RIGL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RIGL as a result. In 63 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
RIGL moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RIGL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
Bullish Trend Analysis
Following a +1.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where RIGL advanced for three days, in 226 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
RIGL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 174 of 210 cases where RIGL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 12 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. RIGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.007) is normal, around the industry mean (2.788). P/E Ratio (2.565) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (3.146) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RIGL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage drug development company that discovers and develops novel, small-molecule drugs
Industry Biotechnology
Advertisement